Climb Bio (CLYM) awards director Douglas Williams 40,000 stock options

Rhea-AI Filing Summary

Climb Bio, Inc. reported that director Douglas E. Williams received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. These options vest on the earlier of June 5, 2027 or immediately before the next annual meeting of stockholders, subject to his continued service. Following this grant, Williams holds 40,000 options directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WILLIAMS DOUGLAS E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 40,000 options Exercise price: $10.55 per share Expiration date: June 4, 2036 +1 more

4 metrics

Options granted 40,000 options Stock Option (Right to Buy) grant to director

Exercise price $10.55 per share Strike price for option grant

Expiration date June 4, 2036 Option term end date

Shares underlying options 40,000 shares Common Stock underlying granted options

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "10.5500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-04T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILLIAMS DOUGLAS E

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MASSACHUSETTS 02481

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.55	06/05/2026		A		40,000		(1)	06/04/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Remarks:

Exhibit Index: 24.1 - Power of Attorney

	Chandra Adams, as Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Climb Bio (CLYM) report in this Form 4 filing?

Climb Bio disclosed that director Douglas E. Williams received a grant of 40,000 stock options. These options give him the right to buy common shares at a fixed price, representing standard equity-based director compensation rather than an open-market transaction.

How many Climb Bio (CLYM) stock options were granted to Douglas E. Williams?

Douglas E. Williams was granted 40,000 stock options. Each option relates to one share of Climb Bio common stock, creating potential future ownership if exercised according to the option terms once vesting conditions are satisfied.

What is the exercise price of the Climb Bio (CLYM) options granted?

The granted stock options have an exercise price of $10.55 per share. This means Williams can later buy Climb Bio common shares at $10.55, regardless of the market price at the time of exercise, once the options are vested.

When do Douglas E. Williams’ Climb Bio (CLYM) options vest?

The options vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders. Vesting is conditioned on Williams’ continued service with Climb Bio through that date, aligning incentives with ongoing board participation.

Are these Climb Bio (CLYM) transactions open-market buys or sales?

No, this Form 4 reflects a grant of stock options as compensation, not an open-market buy or sale. The options were awarded at no cost and become exercisable later, subject to vesting, rather than representing immediate trading activity in Climb Bio shares.

How many Climb Bio (CLYM) options does Williams hold after this grant?

After this grant, Williams holds 40,000 stock options in total, all from this award. These options are held directly and will remain a derivative position until he chooses to exercise them after they vest and before the June 4, 2036 expiration date.